CYBN Stock Summary and Trading Ideas (Cybin Common Shares | AMEX:CYBN)

Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.

Cybin Common Shares trades on the AMEX stock market under the symbol CYBN.

As of January 9, 2026, CYBN stock price was flat at $8.28 with million shares trading.

CYBN has a beta of 1.31, meaning it tends to be more sensitive to market movements. CYBN has a correlation of 0.15 to the broad based SPY ETF.

CYBN has a market cap of $413.20 million. This is considered a Small Cap stock.

In the last 3 years, CYBN traded as high as $13.88 and as low as $.17.

CYBN has underperformed the market in the last year with a price return of -13.4% while the SPY ETF gained +19.0%. However, in the short term, CYBN had mixed performance relative to the market. It has outperformed in the last 3 months, returning +32.1% vs +3.7% return in SPY. But in the last 2 weeks, CYBN shares have been beat by the market, returning -0.7% compared to an SPY return of +0.5%.

CYBN support price is $7.89 and resistance is $8.67 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CYBN shares will trade within this expected range on the day.